Stay updated with breaking news from I Mab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...
- Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients' immune system against cancer cells....
I-Mab (NASDAQ:IMAB – Get Rating) was the recipient of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 2,020,000 shares, an increase of 8.6% from the March 31st total of 1,860,000 shares. Based on an average daily volume of 399,000 shares, the short-interest ratio […]
/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...
Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon's...